Journal
JOURNAL OF NEUROTRAUMA
Volume 32, Issue 4, Pages 221-227Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/neu.2013.3274
Keywords
brain edema; traumatic brain injury; CBF; arginine vasopressin
Funding
- Program for Research and Medical Education (Forderprogramm fur Forschung und Lehre) of the Faculty of Medicine, Ludwig-Maximilians-University, Munich
Ask authors/readers for more resources
The attenuation of brain edema is a major therapeutic target after traumatic brain injury (TBI). Vasopressin (AVP) is well known to play a major role in the regulation of brain water content and vasoendothelial functions and to be involved in brain edema formation. Therefore, the aim of the current study was to analyze the antiedematous efficacy of a clinically relevant, nonpeptidic AVP V-1a and V-2 receptor antagonists. C57Bl6 mice were subjected to controlled cortical impact (CCI) and V-1a or V-2 receptors were inhibited by using the highly selective antagonists SR-49059 or SR-121463A either by systemic (intraperitoneal, IP) or intracerebroventricular (ICV) application. After 24 h, brain edema, intracranial pressure (ICP), and contusion volume were assessed. Systemically applied AVP receptor antagonists could not reduce secondary lesion growth. In contrast, ICV administration of AVP V-1a receptor antagonist decreased brain edema formation by 68%, diminished post-traumatic increase of ICP by 46%, and reduced secondary contusion expansion by 43% 24 h after CCI. The ICV inhibition of V-2 receptors resulted in significant reduction of post-traumatic brain edema by 41% 24 h after CCI, but failed to show further influence on ICP and lesion growth. Hence, centrally applied vasopressin V-1a receptor antagonists may be used to reduce brain edema formation after TBI.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available